Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure

Circulation Journal

Volumn 76, Issue 7, 2012, Pages 1646-1653

  Kobayashi, Shigeki ^a   Susa, Takehisa ^a   Tanaka, Takeo ^a   Murakami, Wakako ^a   Fukuta, Seiko ^a   Okuda, Shinichi ^a   Doi, Masahiro ^a   Wada, Yasuaki ^a   Nao, Tomoko ^a   Yamada, Jutaro ^a   Okamura, Takayuki ^a   Yano, Masafumi ^a   Matsuzaki, Masunori ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute decompensated heart failure; Betas blocker; Inotropic agents; Tachycardia

Indexed keywords

BISOPROLOL; CARVEDILOL; DIURETIC AGENT; LANDIOLOL; MILRINONE; VASODILATOR AGENT;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CLINICAL ARTICLE; DRUG MEGADOSE; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART INDEX; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE FILLING; HEMODYNAMIC MONITORING; HUMAN; LOW DRUG DOSE; MALE; OXYGEN SATURATION; PARADOXICAL PULSE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; PULMONARY ARTERY OCCLUSION PRESSURE; SINUS RHYTHM; SWAN GANZ CATHETER; TACHYCARDIA; TEI INDEX; VASCULAR RESISTANCE;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ARRHYTHMIAS, CARDIAC; CARDIOTONIC AGENTS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HEART RATE; HEMODYNAMICS; HUMANS; JAPAN; MALE; MIDDLE AGED; MILRINONE; MORPHOLINES; PROSPECTIVE STUDIES; PULMONARY WEDGE PRESSURE; RECOVERY OF FUNCTION; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; UREA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84863190423     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0033     Document Type: Article

References (32)

1. Andersson B, Lomsky M, Waagstein F. The link between acute haemodynamic adrenergic β-blockade and long-term effects in patients with heart failure: A study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol. Eur Heart J 1993; 14: 1375-1385.
2. Majure DT, Teerlink JR. Update on the management of acute decompensated heart failure. Curr Treat Options Cardiovasc Med 2011; 13: 570-585.
3. Thomas SS, Nohria A. Hemodynamic classifications of acute heart failure and their clinical application. Circ J 2012; 76: 278-286.
4. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2008; 29: 2388-2442.
5. Hiramitsu S, Miyagishima K, Kimura H, Mori K, Shiino K, Yamada A, et al. Management of severe heart failure. Circ J 2009; 73(Suppl): A-36-A-41.
6. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 2001; 81: 141-149.
7. Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40: 1248-1258.
8. Kumar A, Choudhary G, Antonio C, Just V, Jain A, Heaney L, et al. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 2001; 142: 512-515.
9. Earl GL, Verbos-Kazanas MA, Fitzpatrick JM, Narula J. Tolerability of β-blockers in outpatients with refractory heart failure who were receiving continuous milrinone. Pharmacotherapy 2007; 27: 697-706.
10. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, et al. Combined oral positive inotropic and β-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998; 31: 1336-1340.
11. Gattis WA, O'Connor CM, Leimberger JD, Felker GM, Adams KF, Gheorghiade M. Clinical outcomes in patients on β-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol 2003; 91: 169-174.
12. Zewail AM, Nawar M, Vrtovec B, Eastwood C, Kar MN, Delgado RM 3rd. Intravenous milrinone in treatment of advanced congestive heart failure. Tex Heart Inst J 2003; 30: 109-113.
13. Böhm M, Deutsch HJ, Hartmann D, Rosée KL, Stäblein A. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 1997; 30: 992-996.
14. Hasenfuss G, Teerlink JR. Cardiac inotropes: Current agents and future directions. Eur Heart J 2011; 32: 1838-1845.
15. Endoh M, Yanagisawa T, Taira N, Blinks JR. Effect of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle. Circulation 1986; 73(Suppl III): 117-133.
16. Gwathmey JG, Morgan JP. The effects of milrinone and piroximone on intracellular calcium handling in working myocardium from the ferret. Br J Pharmacol 1985; 85: 97-108.
17. Yoshida Y, Hongo T, Sakamoto A, Ogawa R. Successful management of tachycardiac atrial fibrillation in a septic patient with landiolol. Anesth Analg 2005; 100: 294-295.
18. Yoshida Y, Terajima K, Sato C, Akada S, Miyagi Y, Hongo T, et al. Clinical role and efficacy of landiolol in the intensive care unit. J Anesth 2008; 22: 64-69.
19. Ikeshita K, Nishikawa K, Toriyama S, Yamashita T, Tani Y, Yamada T, et al. Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts. J Anesth 2008; 22: 361-366.
20. Doi M, Yano M, Kobayashi S, Kohno M, Tokuhisa T, Okuda S, et al. Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation 2002; 105: 1374.
21. Kobayashi S, Susa T, Tanaka T, Wada Y, Okuda S, Doi M, et al. Urinary 8-hydroxy-2′-deoxyguanosine reflects symptomatic status and severity of systolic dysfunction in patients with chronic heart failure. Eur J Heart Fail 2011; 13: 29-36.
22. Susa T, Kobayashi S, Tanaka T, Murakami W, Akashi S, Kunitsugu I, et al. Urinary 8-hydroxy-2′-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure. Circ J 2012; 76: 117-126.
23. Fujita T, Ishikawa Y. Apoptosis in heart failure: The role of the β-adrenergic receptor-mediated signaling pathway and p53-mediated signaling pathway in the apoptosis of cardiomyocytes. Circ J 2011; 75: 1811-1818.
24. Maytin M, Colucci WS. Cardioprotection: A new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005; 96: 26G-31G.
25. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation 1992; 85: 1743-1750.
26. Hasenfuss G, Reinecke H, Studer R, Pieske B, Meyer M, Drexler H, et al. Calcium cycling proteins and force-frequency relationship in heart failure. Basic Res Cardiol 1996; 91(Suppl 2): 17-22.
27. Ryan JM, Schive JF, Hull HB, Oser BM. Experiences with pulsus alternans: Ventricular alternation and the stage of heart failure. Circulation 1956; 14: 1099-1103.
28. Hirashiki A, Izawa H, Somura F, Obata K, Kato T, Nishizawa T, et al. Prognostic value of pacing-induced mechanical alternans in patients with mild-to-moderate idiopathic dilated cardiomyopathy in sinus rhythm. J Am Coll Cardiol 2006; 47: 1382-1389.
29. Lab MJ, Lee LA. Changes in intracellular calcium during mechanical alternans in isolated ferret ventricular muscle. Circ Res 1990; 66: 585-595.
30. 2+ handling is the primary cause of mechanical alternans: Study in ferret ventricular muscles. Am J Physiol 1991; 261: H1746-H1755.
31. Györke S, Carnes C. Dysregulated sarcoplasmic reticulum calcium release: Potential pharmacological target in cardiac disease. Pharmacol Ther 2008; 119: 340-354.
32. 2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 2007; 49: 1722-1732.